蒋千琴

蒋千琴

FDA外审顾问

等级 已入驻 排行 文章数 热度
54 1 年 1 541 0

以下是作者 蒋千琴 的最新文章

加载用时:24.4429 毫秒

  • FDA Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products

    FDA Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products

    Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/10/2021 点赞 0 浏览 646 评论 0
  • FDA Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency

    FDA Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency

    Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency[附网盘链接]是Food&Drug Administration于之前发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/10/2021 点赞 0 浏览 271 评论 0
  • FDA Allergic Rhinitis Developing Drug Products for Treatment Guidance for Industry

    FDA Allergic Rhinitis Developing Drug Products for Treatment Guidance for Industry

    Allergic Rhinitis Developing Drug Products for Treatment Guidance for Industry[附网盘链接]是FDA于过去发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/9/2021 点赞 0 浏览 252 评论 0
  • FDA Alcoholism  Developing Drugs for Treatment

    FDA Alcoholism Developing Drugs for Treatment

    Alcoholism Developing Drugs for Treatment[附网盘链接]是FDA于之前发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/9/2021 点赞 0 浏览 200 评论 0
  • FDA Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act

    FDA Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act

    Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act[附网盘链接]是FDA于之前发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/8/2021 点赞 0 浏览 143 评论 0
  • FDA Adverse Accreditation Decisions, SuspensionRevocation of Certificates, or Patient and Physician Notification Orders Draft

    FDA Adverse Accreditation Decisions, SuspensionRevocation of Certificates, or Patient and Physician Notification Orders Draft

    Adverse Accreditation Decisions, SuspensionRevocation of Certificates, or Patient and Physician Notification Orders Draft[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/8/2021 点赞 0 浏览 626 评论 0
  • FDA Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization

    FDA Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization

    Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization[附网盘链接]是FDA于不久前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/7/2021 点赞 0 浏览 153 评论 0
  • FDA Advanced Prostate Cancer Developing Gonadotropin-Releasing Hormone Analogues

    FDA Advanced Prostate Cancer Developing Gonadotropin-Releasing Hormone Analogues

    Advanced Prostate Cancer Developing Gonadotropin-Releasing Hormone Analogues[附网盘链接]是Food&Drug Administration于当前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/7/2021 点赞 0 浏览 165 评论 0
  • FDA Administrative Procedures for CLIA Categorization

    FDA Administrative Procedures for CLIA Categorization

    Administrative Procedures for CLIA Categorization[附网盘链接]是Food And Drug Administration于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/6/2021 点赞 0 浏览 187 评论 0
  • FDA Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products Draft

    FDA Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products Draft

    Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products Draft[附网盘链接]是FDA于过去发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/6/2021 点赞 0 浏览 227 评论 0
  • FDA Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry

    FDA Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry

    Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry[附网盘链接]是FDA于过去发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/5/2021 点赞 0 浏览 545 评论 0
  • FDA Adaptive Designs for Medical Device Clinical Studies

    FDA Adaptive Designs for Medical Device Clinical Studies

    Adaptive Designs for Medical Device Clinical Studies[附网盘链接]是FDA于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/5/2021 点赞 0 浏览 217 评论 0
  • FDA Acute Myeloid Leukemia  Developing Drugs and Biological Products for Treatment Draft

    FDA Acute Myeloid Leukemia Developing Drugs and Biological Products for Treatment Draft

    Acute Myeloid Leukemia Developing Drugs and Biological Products for Treatment Draft[附网盘链接]是Food And Drug Administration于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/4/2021 点赞 0 浏览 132 评论 0
  • FDA Acne Vulgaris  Establishing Effectiveness of Drugs Intended for Treatment

    FDA Acne Vulgaris Establishing Effectiveness of Drugs Intended for Treatment

    Acne Vulgaris Establishing Effectiveness of Drugs Intended for Treatment[附网盘链接]是FDA于过去发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/4/2021 点赞 0 浏览 251 评论 0
  • FDA Acceptance Review for De Novo Classification Requests

    FDA Acceptance Review for De Novo Classification Requests

    Acceptance Review for De Novo Classification Requests[附网盘链接]是Food&Drug Administration于不久之前发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。

    10/3/2021 点赞 0 浏览 351 评论 0